Welcome to our dedicated page for TAKEDA PHARMACEUTICAL CO SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TAKEDA PHARMACEUTICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TAKEDA PHARMACEUTICAL CO's regulatory disclosures and financial reporting.
Takeda Pharmaceutical Company Limited (TAK) – Form 144 filing discloses a planned insider sale of 26,874 American Depositary Shares (ADSs) with an aggregate market value of $414,397.08. The transaction will be executed through Interactive Brokers on the NYSE around 9 July 2025. The seller received the shares as part of restricted stock unit (RSU) awards that vested on 1 July 2025. No prior sales by this individual were reported in the past three months. Relative to the company’s 123.49 million ADSs outstanding, the proposed sale represents roughly 0.02% of shares, suggesting an immaterial dilution impact. The filer certifies no knowledge of undisclosed adverse information. While Form 144 notices can flag insider sentiment, the modest size and routine compensation-related nature of this sale indicate limited market significance.
Takeda Pharmaceutical Company Limited (TAK) has filed a Form 144 indicating a proposed sale of restricted securities.
- Securities to be sold: 4,477 American Depositary Shares (ADSs).
- Estimated market value: US $69,035.34.
- Broker: Interactive Brokers LLC, Greenwich, CT.
- Approximate sale date: 9 July 2025 on the NYSE.
- Shares outstanding: 123,490,548 ADSs – the planned sale represents less than 0.01% of this total.
- Source of shares: Vested Restricted Stock Unit (RSU) awards acquired 1 July 2025 as compensation from Takeda Pharmaceutical Company Limited.
- Prior sales: None reported in the past three months.
The filing is routine and does not include earnings data or announce any strategic transactions. It simply registers a modest insider sale that is immaterial relative to the company’s share base.
Takeda Pharmaceutical Company Limited (NYSE: TAK) has filed a Form 144 indicating a proposed insider sale of American Depositary Shares (ADSs) under Rule 144.
- Securities to be sold: 34,857 ADSs.
- Estimated market value: US$537,494.94.
- Broker: Interactive Brokers LLC, Greenwich, CT.
- Approximate sale date: 09 July 2025.
- Shares outstanding: 123,490,548 ADSs – the planned sale represents roughly 0.028% of the float.
- Source of shares: Vested Restricted Stock Unit awards acquired 01 July 2025 as compensation.
No other securities have been sold by the filer in the past three months and the filer affirms the absence of undisclosed adverse information. As this notice covers a relatively small position and involves previously issued shares, it does not affect Takeda’s share count or capital structure. Investors typically view Form 144 filings as neutral-to-slightly-negative sentiment indicators because they reflect potential insider selling, but the immaterial size here limits market impact.
Takeda Pharmaceutical Company Limited (NYSE: TAK) filed a Form 144 indicating the proposed sale of 169,313 American Depositary Shares (ADSs). The securities were acquired via restricted stock unit (RSU) awards that vested on 07/01/2025 and have an aggregate market value of US$2,610,806.46. The filer plans to sell the shares through Interactive Brokers LLC on or about 07/09/2025. According to the notice, the issuer has 123,490,548 ADSs outstanding, and the planned sale will be executed on the NYSE.
Form 144 is a disclosure of intent, not a confirmation that the sale has occurred. The filing contains no indication of undisclosed adverse information, and no other sales by the filer were reported in the past three months. No financial performance metrics or strategic updates were provided; the document is strictly related to the planned disposition of shares.
This Form 144 filing indicates that an unidentified holder of Takeda Pharmaceutical Company Limited (TAK) American Depositary Shares (ADSs) plans to sell up to 5,608 ADSs through Interactive Brokers on or about 9 July 2025 on the NYSE. The block is valued at roughly $86,475 based on the market price reported in the form. The shares derive from restricted-stock-unit awards that vested on 1 July 2025. With 123.49 million ADSs outstanding, the proposed sale represents only about 0.0045 % of the float, implying immaterial dilution or trading-volume impact. No other sales have been made by the filer in the past three months, and the signer certifies the absence of undisclosed adverse information. While insider sales occasionally raise sentiment concerns, the size and routine compensation origin suggest limited market significance.
Takeda Pharmaceutical Company Limited (TAK) has filed a Form 6-K confirming completion of the previously announced disposal of treasury shares for its Long-Term Incentive Plan (LTIP) covering employees outside Japan.
- Shares disposed: 17,270,941 common shares (down 84,829 shares from the June 10 plan).
- Disposal price: ¥4,336 per share.
- Total value: ¥74,886,800,176 (approximately ¥368 million less than originally anticipated).
- Payment date: 8 July 2025 (unchanged).
- Participants: 10,283 employees (previously 10,346).
The change reflects the partial forfeiture of rights by certain allottees. Management states the adjustment will have an immaterial impact on FY 2025 financial results (fiscal year ending 31 Mar 2026). Because the shares come from existing treasury stock, the transaction generates no cash inflow but modestly increases the public float, implying potential dilution of roughly 1 % of total shares outstanding. Strategically, the action completes Takeda’s equity-based compensation initiative, intended to improve employee alignment with shareholder interests, and has no effect on guidance or core operations.
Takeda Pharmaceutical Company Limited (NYSE: TAK) filed a Form 6-K to furnish debt-financing exhibits related to two new U.S. dollar bond offerings issued through its subsidiary, Takeda U.S. Financing, Inc. The exhibits include the master Indenture dated 2 July 2025 and specimen note forms for:
- $1.65 billion 5.200% Guaranteed Senior Notes due 2035
- $750 million 5.900% Guaranteed Senior Notes due 2055
Legal opinions from Sullivan & Cromwell LLP and Nishimura & Asahi covering the validity of the notes are also provided. All exhibits are incorporated by reference into the company’s shelf Registration Statement on Form F-3 (File Nos. 333-288301 & 333-288301-01) filed on 25 June 2025. The filing contains no additional financial results or strategic commentary beyond the documentation of these debt instruments.